TY  - JOUR
AU  - Đorđević, Vladimir
AU  - Wallace, David
AU  - Schweitzer, Amie
AU  - Boricić, Novica
AU  - Knežević, Đorđe
AU  - Matić, Slavko
AU  - Grubor, Nikola
AU  - Kerkez, Mirko
AU  - Radenković, Dejan
AU  - Bulat, Zorica
AU  - Antonijević, Biljana
AU  - Matović, Vesna
AU  - Buha, Aleksandra
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3346
AB  - Although profoundly studied, etiology of pancreatic cancer (PC) is still rather scarce. Some of established risk factors of PC are connected to an increased cadmium (Cd) body burden. Hence, the aim of this study was to investigate the role of this environmental pollutant in PC development by conducting human observational, experimental and in vitro studies. The case-control study included 31 patients with a histologically based diagnosis of exocrine PC subjected to radical surgical intervention as cases and 29 accidental fatalities or subjects who died of a nonmalignant illness as controls. Animal study included two treated groups of Wistar rats (15 and 30 mg Cd/kg b.w) and untreated control group, sacrificed 24 h after single oral exposure. In in vitro study pancreas hTERT-HPNE and AsPC-1 cells were exposed to different Cd concentrations corresponding to levels measured in human cancerous pancreatic tissue. Cd content in cancer tissue significantly differed from the content in healthy controls. Odds ratio levels for PC development were 2.79 (95% CI 0.91-8.50) and 3.44 (95% CI 1.19-9.95) in the third and fourth quartiles of Cd distribution, respectively. Animal study confirmed Cd deposition in pancreatic tissue. In vitro studies revealed that Cd produces disturbances in intrinsic pathway of apoptotic activity and the elevation in oxidative stress in pancreatic cells. This study presents three different lines of evidence pointing towards Cd as an agent responsible for the development of PC.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Environment International
T1  - Environmental cadmium exposure and pancreatic cancer: Evidence from case control, animal and in vitro studies
VL  - 128
SP  - 353
EP  - 361
DO  - 10.1016/j.envint.2019.04.048
ER  - 

@article{
author = "Đorđević, Vladimir and Wallace, David and Schweitzer, Amie and Boricić, Novica and Knežević, Đorđe and Matić, Slavko and Grubor, Nikola and Kerkez, Mirko and Radenković, Dejan and Bulat, Zorica and Antonijević, Biljana and Matović, Vesna and Buha, Aleksandra",
year = "2019",
abstract = "Although profoundly studied, etiology of pancreatic cancer (PC) is still rather scarce. Some of established risk factors of PC are connected to an increased cadmium (Cd) body burden. Hence, the aim of this study was to investigate the role of this environmental pollutant in PC development by conducting human observational, experimental and in vitro studies. The case-control study included 31 patients with a histologically based diagnosis of exocrine PC subjected to radical surgical intervention as cases and 29 accidental fatalities or subjects who died of a nonmalignant illness as controls. Animal study included two treated groups of Wistar rats (15 and 30 mg Cd/kg b.w) and untreated control group, sacrificed 24 h after single oral exposure. In in vitro study pancreas hTERT-HPNE and AsPC-1 cells were exposed to different Cd concentrations corresponding to levels measured in human cancerous pancreatic tissue. Cd content in cancer tissue significantly differed from the content in healthy controls. Odds ratio levels for PC development were 2.79 (95% CI 0.91-8.50) and 3.44 (95% CI 1.19-9.95) in the third and fourth quartiles of Cd distribution, respectively. Animal study confirmed Cd deposition in pancreatic tissue. In vitro studies revealed that Cd produces disturbances in intrinsic pathway of apoptotic activity and the elevation in oxidative stress in pancreatic cells. This study presents three different lines of evidence pointing towards Cd as an agent responsible for the development of PC.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Environment International",
title = "Environmental cadmium exposure and pancreatic cancer: Evidence from case control, animal and in vitro studies",
volume = "128",
pages = "353-361",
doi = "10.1016/j.envint.2019.04.048"
}

Đorđević, V., Wallace, D., Schweitzer, A., Boricić, N., Knežević, Đ., Matić, S., Grubor, N., Kerkez, M., Radenković, D., Bulat, Z., Antonijević, B., Matović, V.,& Buha, A.. (2019). Environmental cadmium exposure and pancreatic cancer: Evidence from case control, animal and in vitro studies. in Environment International
Pergamon-Elsevier Science Ltd, Oxford., 128, 353-361.
https://doi.org/10.1016/j.envint.2019.04.048

Đorđević V, Wallace D, Schweitzer A, Boricić N, Knežević Đ, Matić S, Grubor N, Kerkez M, Radenković D, Bulat Z, Antonijević B, Matović V, Buha A. Environmental cadmium exposure and pancreatic cancer: Evidence from case control, animal and in vitro studies. in Environment International. 2019;128:353-361.
doi:10.1016/j.envint.2019.04.048 .

Đorđević, Vladimir, Wallace, David, Schweitzer, Amie, Boricić, Novica, Knežević, Đorđe, Matić, Slavko, Grubor, Nikola, Kerkez, Mirko, Radenković, Dejan, Bulat, Zorica, Antonijević, Biljana, Matović, Vesna, Buha, Aleksandra, "Environmental cadmium exposure and pancreatic cancer: Evidence from case control, animal and in vitro studies" in Environment International, 128 (2019):353-361,
https://doi.org/10.1016/j.envint.2019.04.048 . .

TY  - JOUR
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
AU  - Radenković, Dejan
AU  - Gvozdenović, Miomir
AU  - Mitrović, Mihajlo
PY  - 2004
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/557
AB  - Severe pancreatitis occurs in 20%’30% of all patients with acute pancreatitis. Pancreatic enzymes, cytokines and other active peptides, liberated from the inflamed pancreas, convert inflammation of the pancreas as a single-organ disease of the retroperitoneum to a multisystem disease. Determinations of pancreatic serum enzymes are still "the golden standard" for diagnosis of the acute pancreatitis. Out of clinically significant pancreatic enzymes, pancreatic-amylase and lipase are suggested for routine clinical determination due to available methods for their measurement. The methods are simple, and the results may be obtained rather quickly without any special equipment. Maximal diagnostic accuracy is achieved by "cut-off" values of 182 U/L for pancreatic-amylase and 656 U/L for lipase. Treatment of patients with acute pancreatitis is based on the initial assessment of disease severity. Early staging is based on the presence and degree of systemic failure (cardiovascular, pulmonary, and renal) and on the presence and extent of pancreatic necrosis. Individual clinical parameters and laboratory biomarkers, although sometimes helpful, are not sufficiently accurate to reliable assess the severity of an acute attack. Numeric grading systems with sensitivities of about 70% are commonly used today as indicators of organ failure and disease severity. Contrast material-enhanced computed tomography is used in addition to help evaluate local pancreatic morphology and the presence and extent of pancreatic necrosis. Out of all recently studied biochemical parameters for prognostic evaluation of acute pancreatitis patients, the measurement of C-reactive protein concentration appeared to be the parameter with the highest clinical accuracy. The best differentiation of moderate from severe acute pancreatitis forms is achieved by "cut-off" CRP values of 126 mg/L, 48 hours from the onset of symptoms. For this reason, CRP measurement may be used as the alternative to computerized tomography. In compliance with the postulations for evidence- based medicine, the procedures related to diagnosis, prognosis and management of acute pancreatitis are classified into four categories: certain, probable, possible and inappropriate.
AB  - Težak oblik bolesti se javlja kod 20%’30% pacijenata sa akutnim pankreatitisom. Oslobađanje pankreasnih enzima, citokina i drugih aktivnih peptide iz pankreasa zahvaćenog inflamacijom uzrokuje prelaz od zapaljenja jednog organa u retroperitoneumu ka multisistemskom oboljenju. Određivanje pankreasnih enzima u serumu još uvek ostaje "zlatan standard" u dijagnozi akutnog pankreatitisa. Od klinički važnih pankreasnih enzima za kliničko rutinsko određivanje preporučuju se pankreasna a-amilaza i lipaza zbog postojanja raspoloživih metoda za njihovo određivanje. Metode su jednostavne, rezultat može da se dobije dosta brzo i ne zahteva posebnu opremu za određivanje. Maksimalna dijagnostička tačnost se postiže pri "cut-off" vrednostima od 182 U/L za pankreasnu a-amilazu i 656 U/L za lipazu. Tretman pacijenata sa akutnim pankreatitisom se zasniva na inicijalnoj proceni težine oboljenja. Rana gradacija se zasniva na prisustvu i stepenu sistemskih oštećenja (kardiovasdkularnih, pulmonalnih i renalnih), kao i na prisustvu i veličini pankreasne nekroze. Mada individualni klinički parametri i laboratorijski biomarkeri mogu da budu od pomoći, to nije dovoljno tačno u proceni težine napada. Brojni "sistemi scorova" koriste se danas kao indikatori oštećenja organa i težine oboljenja i njihova osetljivost iznosi oko 70%. Kompjuterizovana tomografija poboljšana kontrastom se koristi za dodatnu evaluaciju lokalne pankreasne morfologije, kao i stepena pankreasne nekroze. Od svih do sada ispitivanih biohemijskih parametara za prognostičku evaluaciju pacijenata sa akutnim pankreatitisom, određivanje koncentracije C-reaktivnog proteina (CRP) predstavlja parametar sa najvećom kliničkom tačnošću. Najbolje razlikovanje blagih od teških oblika AP se postiže pri "cut-off" vrednosti CRP od 126 mg/L i to 48 sati od početka simptoma. Iz ovih razloga određivanje CRP može da se koristi kao alternativa kompjuterizovanoj tomografiji. U skladu sa postulatima na kojima se zasniva medicina zasnovana na dokazima (eng. evidence-based medicine) postupci vezani za prognozu i tretman akutnog pankreatitisa se klasifikuju u četiri kategorije: izvesni, verovatni, mogući i neodgovarajući.
PB  - Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd
T2  - Jugoslovenska medicinska biohemija
T1  - Diagnosis, assessment of severity and management of acute pancreatitis
T1  - Dijagnoza, procena težine i menadžment akutnog pankreatitisa
VL  - 23
IS  - 3
SP  - 229
EP  - 233
DO  - 10.2298/JMH0403229I
ER  - 

@article{
author = "Ignjatović, Svetlana and Majkić-Singh, Nada and Radenković, Dejan and Gvozdenović, Miomir and Mitrović, Mihajlo",
year = "2004",
abstract = "Severe pancreatitis occurs in 20%’30% of all patients with acute pancreatitis. Pancreatic enzymes, cytokines and other active peptides, liberated from the inflamed pancreas, convert inflammation of the pancreas as a single-organ disease of the retroperitoneum to a multisystem disease. Determinations of pancreatic serum enzymes are still "the golden standard" for diagnosis of the acute pancreatitis. Out of clinically significant pancreatic enzymes, pancreatic-amylase and lipase are suggested for routine clinical determination due to available methods for their measurement. The methods are simple, and the results may be obtained rather quickly without any special equipment. Maximal diagnostic accuracy is achieved by "cut-off" values of 182 U/L for pancreatic-amylase and 656 U/L for lipase. Treatment of patients with acute pancreatitis is based on the initial assessment of disease severity. Early staging is based on the presence and degree of systemic failure (cardiovascular, pulmonary, and renal) and on the presence and extent of pancreatic necrosis. Individual clinical parameters and laboratory biomarkers, although sometimes helpful, are not sufficiently accurate to reliable assess the severity of an acute attack. Numeric grading systems with sensitivities of about 70% are commonly used today as indicators of organ failure and disease severity. Contrast material-enhanced computed tomography is used in addition to help evaluate local pancreatic morphology and the presence and extent of pancreatic necrosis. Out of all recently studied biochemical parameters for prognostic evaluation of acute pancreatitis patients, the measurement of C-reactive protein concentration appeared to be the parameter with the highest clinical accuracy. The best differentiation of moderate from severe acute pancreatitis forms is achieved by "cut-off" CRP values of 126 mg/L, 48 hours from the onset of symptoms. For this reason, CRP measurement may be used as the alternative to computerized tomography. In compliance with the postulations for evidence- based medicine, the procedures related to diagnosis, prognosis and management of acute pancreatitis are classified into four categories: certain, probable, possible and inappropriate., Težak oblik bolesti se javlja kod 20%’30% pacijenata sa akutnim pankreatitisom. Oslobađanje pankreasnih enzima, citokina i drugih aktivnih peptide iz pankreasa zahvaćenog inflamacijom uzrokuje prelaz od zapaljenja jednog organa u retroperitoneumu ka multisistemskom oboljenju. Određivanje pankreasnih enzima u serumu još uvek ostaje "zlatan standard" u dijagnozi akutnog pankreatitisa. Od klinički važnih pankreasnih enzima za kliničko rutinsko određivanje preporučuju se pankreasna a-amilaza i lipaza zbog postojanja raspoloživih metoda za njihovo određivanje. Metode su jednostavne, rezultat može da se dobije dosta brzo i ne zahteva posebnu opremu za određivanje. Maksimalna dijagnostička tačnost se postiže pri "cut-off" vrednostima od 182 U/L za pankreasnu a-amilazu i 656 U/L za lipazu. Tretman pacijenata sa akutnim pankreatitisom se zasniva na inicijalnoj proceni težine oboljenja. Rana gradacija se zasniva na prisustvu i stepenu sistemskih oštećenja (kardiovasdkularnih, pulmonalnih i renalnih), kao i na prisustvu i veličini pankreasne nekroze. Mada individualni klinički parametri i laboratorijski biomarkeri mogu da budu od pomoći, to nije dovoljno tačno u proceni težine napada. Brojni "sistemi scorova" koriste se danas kao indikatori oštećenja organa i težine oboljenja i njihova osetljivost iznosi oko 70%. Kompjuterizovana tomografija poboljšana kontrastom se koristi za dodatnu evaluaciju lokalne pankreasne morfologije, kao i stepena pankreasne nekroze. Od svih do sada ispitivanih biohemijskih parametara za prognostičku evaluaciju pacijenata sa akutnim pankreatitisom, određivanje koncentracije C-reaktivnog proteina (CRP) predstavlja parametar sa najvećom kliničkom tačnošću. Najbolje razlikovanje blagih od teških oblika AP se postiže pri "cut-off" vrednosti CRP od 126 mg/L i to 48 sati od početka simptoma. Iz ovih razloga određivanje CRP može da se koristi kao alternativa kompjuterizovanoj tomografiji. U skladu sa postulatima na kojima se zasniva medicina zasnovana na dokazima (eng. evidence-based medicine) postupci vezani za prognozu i tretman akutnog pankreatitisa se klasifikuju u četiri kategorije: izvesni, verovatni, mogući i neodgovarajući.",
publisher = "Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd",
journal = "Jugoslovenska medicinska biohemija",
title = "Diagnosis, assessment of severity and management of acute pancreatitis, Dijagnoza, procena težine i menadžment akutnog pankreatitisa",
volume = "23",
number = "3",
pages = "229-233",
doi = "10.2298/JMH0403229I"
}

Ignjatović, S., Majkić-Singh, N., Radenković, D., Gvozdenović, M.,& Mitrović, M.. (2004). Diagnosis, assessment of severity and management of acute pancreatitis. in Jugoslovenska medicinska biohemija
Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd., 23(3), 229-233.
https://doi.org/10.2298/JMH0403229I

Ignjatović S, Majkić-Singh N, Radenković D, Gvozdenović M, Mitrović M. Diagnosis, assessment of severity and management of acute pancreatitis. in Jugoslovenska medicinska biohemija. 2004;23(3):229-233.
doi:10.2298/JMH0403229I .

Ignjatović, Svetlana, Majkić-Singh, Nada, Radenković, Dejan, Gvozdenović, Miomir, Mitrović, Mihajlo, "Diagnosis, assessment of severity and management of acute pancreatitis" in Jugoslovenska medicinska biohemija, 23, no. 3 (2004):229-233,
https://doi.org/10.2298/JMH0403229I . .